Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Precision Business Insights
www.precisionbusinessinsights.com
Rajesh k
sales@precisionbusinessinsights.com
Precision Business Insights, Kemp House, 152 – 160 City Road,
EC1V 2NX

Bookmark and Share
Hepatitis C Treatment Market by Drug class, Route of administration and Distribution channel
Hepatitis C Treatment Market by Drug class Polymerase Inhibitors, NS5A Inhibitors, Interferons, HCV protease inhibitors Combination Therapy), Route of administration(Oral and Parenteral) and Distribution channel (Pharmacies and Others)

BriefingWire.com, 1/14/2019 - Hepatitis C is an infectious disease caused by Hepatitis C virus (HCV) and affects primarily the liver. Hepatitis C is commonly caused by blood to blood contacts such as intravenous drug use, unsterilized equipment and blood transfusions. Hepatitis C may also cause from mother to fetus during birth. People with alcoholism and HIV infection of any age group are at increased risk

Changing aspects of global hepatitis C treatment market

The global Hepatitis C treatment market is boosting due to following factors-

• Increased cases and awareness about the HCV infection

• Government initiatives and various policies helping the cause

• Increasing fund in R & D activities

• New and innovative drug production

Though, absence of antibiotics, expensive medications, and dearth of hepatitis C infection awareness in underdeveloped countries can hamper the market growth of hepatitis C treatment globally.

Market summary:

According to the World Health Organization (WHO), there are 80 Mn people worldwide suffering from chronic hepatitis C virus (HCV),. Collaborations, acquisitions and mergers, new product launches, increase in R & D activities, and sanctions for new products from various drug regulatory bodies such as U.S. FDA are some key tactics followed by various businesses to boost their market growth in global Hepatitis C treatment market.

Read more Insights at www.precisionbusinessinsights.com/market-reports/global-hepatitis-c-treatment-market/

Notable market development:

Mavyret (Glecaprevir/Pibrentasvir) by AbbVie received FDA approval in 2017 for treatment of chronic hepatitis C virus (HCV) infection in all major genotypes (GT1-6)

Some of the key players in the global Hepatitis C treatment market are

• GlaxoSmithKline, plc. (U.K.)

• Bristol-Myers Squibb (U.S)

• F. Hoffmann- La Roche Ltd. (Switzerland)

• Merck & Co, Inc. (U.S)

• Johnson & Johnson Services, Inc. (U.S.)

• Gilead Sciences (U.S.)

• AbbVie Inc. (U.S.)

• Vertex Pharmaceuticals Inc. (U.S.)

• Kadmon Holdings, Inc. (U.S.)

Avail sample report at bit.ly/2RUfDt3

The global Hepatitis C treatment market is categorized on the basis of drug class, route of administration, end-users and geographical regions.

By drug class

• Polymerase Inhibitors

• NS5A Inhibitors

• Interferons

• HCV protease inhibitors

• Combination Therapy

By route of administration

• Oral

• Parenteral

By end-users

• Retail Pharmacies

• Hospital Pharmacies

• Others

By geographical regions

• North America

• Latin America

• Asia Pacific

• The Middle East and Africa

• Europe

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact us

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US):+1-866-598-1553

Website @https://www.precisionbusinessinsights.com

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2019 Proserve Technology, Inc.